Status:
COMPLETED
Oncotype DX in BRCA-mutated Breast Cancer Patients: Our Experience. A Retrospective Observational Monocentric Study
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Breast Cancer
Genetic Predisposition
Eligibility:
FEMALE
18+ years
Brief Summary
The study aims to evaluate the distribution of the Oncotype DX RS® genomic test in patients with ER-positive and HER2-negative breast cancer treated from January 2012 to December 2021, focusing on pat...
Detailed Description
In the past decades, genetic testing for cancer susceptibility has become essential in breast cancer (BC) management. Up to 10% of BC cases are associated with an inherited mutation in various genes, ...
Eligibility Criteria
Inclusion
- Age at diagnosis at least 18 years
- Women who underwent breast surgery in OSR
- Patients with ER-positive, HER2-unamplified early-stage BC who underwent the Oncotype DX assay, according to the standard of care.
Exclusion
- Male
- ER negative or HER2 amplified disease
- Patient s who did not undergo breast surgery in OSR
- Patient s who did not undergo the Oncotype Dx assay
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06484725
Start Date
January 1 2012
End Date
June 30 2022
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Ospedale San Raffaele
Milan, MI, Italy, 20132